Adalimumab (a fully human anti-tumour necrosis factor alpha monoclonal antibody) in the treatment of active rheumatoid arthritis: the initial results of five trials.

Authors
Category Primary study
JournalAnnals of the rheumatic diseases
Year 2002

This article is included in 3 Systematic reviews Systematic reviews (3 references)

This article is part of the following publication threads:
  • ARMADA - DE009 [Anti-TNF Research Study Program of the Monoclonal Antibody Adalimumab [D2E7] in Rheumatoid Arthritis] (5 documents)
  • DE007 [Adalimumab for rheumatoid arthritis [provisional name]] (3 documents)
  • DE001/003 [Adalimumab for rheumatoid arthritis [provisional name]] (2 documents)
  • DE004 [Adalimumab for rheumatoid arthritis [provisional name]] (2 documents)
  • DE010 [Adalimumab for rheumatoid arthritis [provisional name]] (2 documents)
This article is part of the following matrixes of evidence:
Loading references information
This article has no abstract
Epistemonikos ID: a628057c66367aaa7de5f5252cd3f6c521246f61
First added on: Nov 15, 2012